Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2016

Jul 6, 2016

30718_dirs_2016-07-06_ed56142a-7136-4c36-b054-88fca42e6d0d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2016-07-01

Reporting Person: Eansor Norman David (SVP - Novus Biologicals)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-07-01 Common Stock F 533 $112.24 Disposed 3936 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $94.35 2021-08-12 Common Stock (15000) 15000 Direct
Stock Option (Right to Buy) $108.49 2022-08-07 Common Stock (9375) 9375 Direct
Restricted Stock Units $ Common Stock (1500) 1500 Direct

Footnotes

F1: The reporting person has elected to satisfy his tax withholding obligation in connection with the vesting of a prior restricted stock unit grant by directing the Company to withhold shares otherwise issuable pursuant to the previously reported grant.

F2: Includes 1,666 shares of restricted stock units that vest on 7/1/17.

F3: 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

F4: Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.